Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Health Policy (Amsterdam, Netherlands)|October 28, 1999
Towards a reinforced agency role of health insurers in Belgium and The NetherlandsF T Schut, E K van DoorslaerSocial Science & Medicine (1982)|January 1, 1989
"A built bed is a filled bed?" An empirical re-examinationE K van Doorslaer, R C van VlietSocial Science & Medicine (1982)|July 1, 1992
Economic appraisal of asthma and COPD care: a literature review 1980-1991M P Mölken, E K Van Doorslaer, F F RuttenPharmacoeconomics|May 27, 1999
Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthmaM P Rutten-van Mölken, E K van Doorslaer, M D TillHealth Economics|September 1, 1994
Statistical analysis of cost outcomes in a randomized controlled clinical trialM P Rutten-van Mölken, E K van Doorslaer, R C van VlietMedical Care|September 1, 1995
Methodological issues of patient utility measurement. Experience from two clinical trialsM P Rutten-van Mölken, C H Bakker, E K van Doorslaer, et al.American Journal of Respiratory and Critical Care Medicine|April 1, 1995
Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary diseaseM P Rutten-van Mölken, E K Van Doorslaer, M C Jansen, et al.Chest|November 1, 1992
Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of lifeC P van Schayck, M P Rutten-van Mölken, E K van Doorslaer, et al.Pharmacoeconomics|September 5, 1993
Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthmaM P Rutten-van Mölken, E K Van Doorslaer, M C Jansen, et al.Dermatology (Basel, Switzerland)|January 1, 1996
Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in GermanyE K Van Doorslaer, G Tormans, A K Gupta, et al.Pageof 2